About
133
Publications
7,693
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
949
Citations
Introduction
Skills and Expertise
Publications
Publications (133)
Introduction: Time-limited ibrutinib plus venetoclax (Ibr+Ven) demonstrated superior PFS, overall survival (OS), and time to next treatment (TTNT) vs chlorambucil plus obinutuzumab (Clb+O) in elderly or comorbid pts with untreated CLL in the GLOW study (Niemann et al. Lancet Oncol 2023). Longer FU provides insight into the sustained benefit of Ibr+...
Aim. To evaluate the effectiveness and safety of Extimia® BIOCAD (international non-proprietary name: empegfilgrastim) to reduce the incidence and duration of neutropenia, the incidence of febrile neutropenia (FN) and infections associated with FN in patients with lymphoproliferative diseases receiving myelosuppressive therapy. Materials and method...
Aim. To study the prognostic significance of gene mutations and intracellular signaling pathways involved in lymphomagenesis in patients with follicular lymphoma using next generation sequencing (NGS).
Materials and methods. The prospective study included 26 patients with a median age of 51.5 years. Mutational screening was performed for cohort usi...
Introduction : In the GLOW trial (NCT03462719), fixed-duration Ibr+Ven treatment has shown superiority to Clb+O in progression-free survival (PFS), better sustained undetectable minimal residual disease (uMRD) responses, and overall survival (OS) benefit in patients with previously untreated chronic lymphocytic leukemia (CLL) who are older and/or h...
Introduction: A frequent clinical manifestation of Ph-negative myeloproliferative neoplasms (MPN) is the development of thrombosis. To identify the state of hypercoagulation it is relevant and promising to introduce global tests for evaluating the hemostasis — the thrombin generation test (TGT) and thromboelastography (TEG).
Aim: to evaluate the pa...
Purpose:
In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it...
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of therapy. BTK plays a key role in all stages of B lymphocyte development, but in recent years, th...
Introduction
Tyrosine kinase inhibitor (TKI) therapy has greatly improved the prognosis of patients with chronic myeloid leukemia (CML), improving the survival expectancy of patients with chronic phase (CP) CML to that of the general population. However, despite these advances, nearly 50% of patients with CP CML experience failure to respond to fro...
Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (CML-CP) treated with ≥2 prior tyrosine kinase inhibitors (TKIs). In ASCEMBL, patients with CML-CP treated with ≥2 prio...
Context:
Peripheral blood stem cells (PBSCs) autologous transplantation is the standard care for transplant-eligible patients with multiple myeloma (MM). This treatment option is somewhat limited due to the high consumption of economic resources and the access to Cryobank.
Objective:
Compare the results of autologous transplantation using non-cr...
Context:
Core-binding factor acute myeloid leukemias (CBF-AML) in different classifications are referred to the group with a favorable prognosis, but 30-50% of patients could have relapses from the disease.
Objective:
To characterize the mutational profile of patients with CBF-AML using next-generation sequencing.
Methods:
13 patients with inv...
Context:
Over the past decade NGS has expanded our understanding of the genomic landscape of hematological malignancies. New biomarkers discovered during NGS are now widely used in clinical practice to improve diagnosis, stratify patients into prognostic groups, and select targeted therapy for Ph-MPN patients.
Objective:
To assess possibilities...
Context:
Preliminary stratification into prognostic risk groups is a mandatory component of the AML patient's treatment, which allows for optimizing the intensity of chemotherapy (CT), as well as planning and justifying allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Objective:
To evaluate the effects of the FLT3 gene mutational...
Context:
Asciminib is the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP). In the ASCEMBL primary analysis, among patients with CML-CP after ≥2 prior TKIs, asciminib resulted in improved major molecular response (MMR, 25.5% vs. 13.2%) at week 24 and fewer grade ≥3 adverse events (AEs) or AEs leading to treatment d...
Context:
Minimal residual disease (MRD) is a predictive marker for progression-free survival (PFS) in chronic leukocytic leukemia (CLL) following chemoimmunotherapy and fixed-duration treatment with venetoclax and anti-CD20 antibodies. This has not been explored for ibrutinib+venetoclax (Ibr+Ven), a fixed-duration treatment with mechanisms of acti...
Context:
Despite success in chronic myeloid leukemia (CML) treatment there are unmet needs third-line therapy.
Objective:
To determine the efficacy and factors influencing the long-term outcomes of third-line therapy with tyrosine kinase inhibitors (TKIs).
Design:
Multicenter retrospective study was conducted in 2019.
Patients or other partic...
Multiple myeloma and chronic lymphocytic leukemia are oncological diseases of the blood, which remain incurable today. The paper proposes a method for classifying blood serum samples from patients with multiple myeloma, chronic lymphocytic leukemia and healthy donors based on the analysis of their spectra in the mid-infrared (IR) range. IR spectra...
BACKGROUND: GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-venetoclax in older patients and/or those with comorbidities with previously untreated chronic lymphocytic leukemia (CLL). METHODS: We randomly assigned (1:1) patients 65 years of age or older or those 18 to 64 years of age who also had a Cumulative Illness Rating S...
7004
Background: Asciminib is the first BCR::ABL1 inhibitor to specifically target the ABL Myristoyl Pocket (STAMP). In the ASCEMBL primary analysis, asciminib had superior efficacy and better safety/tolerability than BOS in pts with CML-CP after ≥2 prior TKIs. After a median follow-up of 2.3 years (16.5 months’ additional follow-up since primary a...
Aim. To assess effectiveness and safety of Extimia BIOCAD (INN: empegfilgrastim) used to decrease the rate and duration of neutropenia, the rate of febrile neutropenia and infections that manifest in febrile neutropenia in patients with lymphoproliferative diseases who receive myelosuppressive therapy.
Materials and methods. The paper presents the...
Background. An autologous stem cell transplant (ASCT) is the standard of treatment young and fit patients with multiple myeloma (MM). The using this method of treatment is limited due to the high consumption of economic and intellectual resources, the low availability of Cryobank departments in regions of Russia.Objective: to evaluate the efficacy...
Background . Over the past 15 years, the therapeutic breakthrough in the treatment of multiple myeloma observed primarily due to the emergence of new drugs. Since the characteristic of the disease is a chronic course with consecutive periods of remissions and relapses, the search for new effective treatment options with each subsequent relapse/prog...
Background. The national observational program MPN-QoL-2020 was focused on quality of life (QoL) and symptoms in patients with classical Ph-negative myeloproliferative neoplasms (MPNs) in the Russian Federation, as well as on the perception of the disease and treatment from the patient's and physician's perspective. Aim. To evaluate QoL in patients...
Background. The introduction of tyrosine kinase inhibitors (TKIs) into real-world clinical practice considerably improved the prognosis for patients with chronic myeloid leukemia (CML). However, during long-term follow-up, almost 1/2 and 2/3 of patients in the chronic phase (CP) discontinue TKI therapy of the first or second line, respectively. Acc...
Features of charge transfer and dielectric relaxation processes in blood serum samples of patients with oncohematological diseases and healthy donors were investigated by dielectric spectroscopy method. The observed features of the dielectric spectra for donors and patients, namely the decrease in conductivity in the high frequency region, the corr...
Background: MRD status is an established predictive marker for progression-free survival (PFS) in CLL following chemoimmunotherapy as well as for fixed-duration treatment with venetoclax and an anti-CD20 antibody. To date, this relationship has not been explored for the combination of Ibr+Ven, an all-oral, once-daily, fixed-duration treatment with...
The results of long-term follow-up of patients (pts) with chronic myeloid leukemia (CML) do not lose their importance. Data from routine clinical practice are of particular interest. The use of 1 st (imatinib, IM) and 2nd generation TKI (2G TKI) led to a significant increase in survival, so the probability of death associated with CML could be sign...
INTRODUCTION: Asciminib is the first BCR-ABL1 inhibitor that potently inhibits kinase activity of the BCR-ABL1 oncoprotein by Specifically Targeting the ABL Myristoyl Pocket (STAMP). The primary analysis from ASCEMBL, a randomized, phase 3 trial, demonstrated that asciminib has superior efficacy and a better safety and tolerability profile than bos...
Multiple myeloma (MM) is a serious disease that is difficult to diagnose especially at early stage. Infrared spectroscopy is a promising approach for diagnosing MM. The principal component analysis (PCA) allows us to reduce the dimension of the data and keep only the important variables. In this study, we apply principal components analysis to infr...
One of the promising approaches for diagnosing oncohematological diseases is infrared spectroscopy of blood serum. In this work secondary structure of blood serum proteins of patients with multiple myeloma, chronic lymphocytic leukemia and healthy donors was studied using IR spectroscopy. As a result of the study, it was found that the secondary st...
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes due to disease biology and inadequate efficacy and/or safety of current therapies. Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhib...
Breast cancer is still the leading cause of death in patients with malignant tumors. Among women with breast cancer, standard combination chemotherapy with anthracyclines and taxanes reduces mortality from this disease by about one third compared to patients not receiving chemotherapy and is the standard for neoadjuvant or adjuvant chemotherapy of...
Aim. To assess the efficacy and safety of using the drug Extimia BIOCAD (international nonproprietary name INN: empegfilgrastim) in order to reduce the frequency and duration of neutropenia, the frequency of febrile neutropenia (FN) and infections manifested by FN in patients with lymphoproliferative diseases receiving myelosuppressive therapy. Mat...
In this work we designed, synthesized and characterized luminescent metal nanoclusters (NCs) on human serum albumin (HSA) and immunoglobulins (Ig). We demonstrate that the approach developed allows one to determine the relative content of albumins and immunoglobulins in biologically relevant protein mixtures based on the luminescent properties of t...
In this paper the dielectric spectra of blood serum of chronic lymphocytic leukemia patients and healthy donors were revealed at room temperature in the frequency range f = 10⁶ – 10⁹ Hz. The relaxation parameters of the systems under study were estimated in the Havriliak-Negami approximation for the electric modulus. The decrease of the electrical...
Introduction: Asciminib, unlike all approved TKIs that bind to the ATP site of the BCR-ABL1 oncoprotein, is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor with a new mechanism of action. BOS, an ATP-competitive TKI, has shown clinical efficacy in pts who received ≥2 TKIs and in newly diagnosed CML, in prospective...
Introduction.In recent times, more and more data are available on the mechanisms of development of primary and secondary resistance to therapy with tyrosine kinase inhibitors (TKIs) in patients with CML. The use of next-generation sequencing (NGS) allows detecting mutations in theBCR-ABLkinase domain (KD) in some patients with resistance to TKI the...
Background: Rapid progress in next-generation sequencing (NGS) technologies make it possible to spell out the mutational status, the genetic and epigenetic variability of chronic lymphocytic leukemia (CLL). The identification of driver mutations allows us to expand understanding of the pathogenesis of CLL, to identify prognostic groups and to selec...
A comparative analysis of the secondary structure of blood serum proteins was carried out in patients with multiple myeloma, chronic lymphocytic leukemia and in healthy donors. The secondary structure of proteins in serum was determined using an infrared spectroscopy method. It was demonstrated that the proposed approach allows one to register a de...
Anemia in patients with malignant neoplasms affects the quality of life of the patient and sometimes limits the timely implementation of antitumor treatment. In the pathogenesis of anemia of the malignant neoplasms the largest role play infiltration of the bone marrow by tumor cells, suppression of hematopoiesis by inflammation cytokines, developme...
Subject of Research. The paper presents testing and evaluation of the spectral method potential capabilities in relation to the study of human blood serum in normal and in patients with multiple myeloma. The study of samples of native and lyophilized serum is carried out in comparison with the spectral characteristics of aqueous extracts of animal...
Anemic syndrome is common in 1/3 of the population, including iron deficiency anemia - in 1,5 billion people. Geriatric patients are one of the main risk group for anemia. Iron deficiency and iron deficiency anemia lead to a decrease in quality of life, an increase in morbidity and mortality, what requires timely diagnosis and treatment. The diagno...
Infrared spectroscopy of biomolecules is one of the few methods, which combine a relatively simple measurements and a possibility of highly informative structural analysis. The most high-demand field of such investigations is the identification of various pathologies accompanied by changes in the biomolecular structure. In this study the comparativ...
Aim. To study the relationship of karyotype, JAK2, CALR, and MPL driver mutations and ASXL1 mutation status with the progression and prediction of primary myelofibrosis (PMF).
Materials & Methods. The trial included 110 PMF patients (38 men and 72 women), median age was 59 years (range 18–82) with median follow-up after diagnosis of 2.6 years (ran...
Background
Acute myeloid leukemia (AML) is a group of diseases with various chromosomal aberrations (CA) and genetic abnormalities that have different prognostic significance. Approximately 45% of patients are not diagnosed with CA, which have intermediate risk. The prognosis of patients with normal karyotype (NK) is heterogeneous and requires stra...
Background
Thrombotic complications contribute significantly to morbidity and mortality in Ph‐negative myeloproliferative neoplasms, including primary myelofibrosis (PMF). The majority of PMF patients have JAK2V617F mutation that is associated with increased thrombotic risk, CALR gene mutations are also common in PMF. Clonal myeloproliferation in P...
Background
According to various authors, the frequency of concurrent myelodysplastic syndrome (MDS) in patients with chronic lymphocytic leukemia (CLL) is 5%. The observation of patients with combination of lympho‐ and myeloproliferative diseases is clinical interest, due to the rare occurrence, poorer outcomes and absence of optimal treatment stra...
Background
Myeloproliferative neoplasms (MPNs) are characterized by an increased frequency of thrombotic complications. Patients with MPNs show little or no abnormalities in traditional coagulation tests. Chronic inflammation associated with pathological secretion of several inflammatory cytokines leads to activation of endothelial cells and imbala...
Background
The insertion of the central venous catheter (CVC) is a vascular access method used in resuscitation and oncohematology and it is required during intensive infusion and chemotherapy. However, due to the invasiveness of the procedure, complications are possible due to the procedure and course of the underlying disease.
Aims
Assess the fr...
Background
High‐dose chemotherapy (HDCT) followed by autologous transplantation of hematopoietic stem cells (auto‐HSCT) is an important component of treatment in multiple myeloma (MM). There is a standard method of controlled cryopreservation of HSC suspension. We found that the storage of native HSC suspension with temperature fluctuations from +3...
Background
Multiple myeloma remains an incurable disease despite the emergence of new drugs. The search of optimal therapeutic strategy to increase life expectancy and remission in patients with this disease is continues. This is facilitated to the achievement of the maximum possible response and eradication of residual tumor load. Existing recomme...
Background
Aplastic anemia (AA) is severe blood system disease, in which more than half of patients may have PNH clone, and there may occur associated variants AA with PNH (AA/PNH). The most frequently observed is the development of classical hemolytic PNH at AA remission, but possibly a combination of the two diseases. For such cases, there is a p...
Background
Over the past two decades, with the advent of new drugs, the tactics of treatment of patients with multiple myeloma (MM) has changed significantly; however, the general problem of the effectiveness of MM therapy remains unresolved to date. This disease is characterized by a progressive course and development of resistance to both proteas...
Background & Aims. Paroxysmal nocturnal hemoglobinuria (PNH) is a disease caused by an acquired clonal disorder of hematopoietic stem cells with clone cell membrane hypersensitivity to the complement. PNH can exist as an independent disease and can also be associated with other pathological conditions characterized by bone marrow deficiency, first...
Detection of FLT3 gene mutations in acute myeloid leukemia is now recognized as an unfavorable factor that affects the disease course, emerging the risk of relapses and overall survival shortening and disease-free survival of patients. The aim of the study was to determine the frequency of mutations of the gene FLT3 and to assess their impact on cl...
A combination of high-resolution agarose gel protein electrophoresis, refractometric analysis, and infrared spectroscopy was applied to investigate the blood serum in patients with multiple myeloma (MM). Analysis of the FTIR spectra of the serum obtained from MM patients and healthy donors revealed a decreased amount of α-helixes and increased cont...
Aim. To analyze the effect on prognosis of mutations that are typical of acute myeloid leukemia (AML) patients.
Materials & Methods. The study included 620 AML patients surveyed at Hematology Clinics of Saint Petersburg (Russia) and Charite Clinic (Berlin, Germany). G-banding of chromosomes was employed for cytogenetic testing. Aberration screenin...
The frequency of gastrointestinal bleeding in the modern structure of emergency surgical pathology still occupies a leading position. In this case, the predominant localization of sources-the stomach and duodenum, as well as the colon and rectum. The literature describes a few observations of severe life-threatening bleeding from tumours of the sma...
Aim. To establish correlation between CD34+ autologous hematopoietic stem cell (HSC) count and colony-forming units (CFU) in the same peripheral blood apheresis product samples before and after cryopreservation in multiple myeloma and lymphoma patients, and to assess clinical value of these parameters.
Materials & Methods. Cell samples of peripher...
Aim. To evaluate the clinical experience of bosutinib use for treatment of chronic myeloid leukemia (CML) patients with intolerance and resistance to other tyrosine kinase inhibitors (TKI), as well as to compare the obtained results with the data of clinical trials.
Materials & Methods. The analysis was conducted on case history records of 51 CML...
The serum of patients with multiple myeloma was examined by refractometric methods before and after the course of antitumor therapy. It was found that the amount of protein in the serum of patients with multiple myeloma, determined by the value of the serum refractive index, tended to decrease after the course of treatment. The value of the refract...
Currently there is no established standard of care for Hodgkin’s disease (HD) in Russian Federation (RF). The mortality from HD in RF is 28,3%, thus improvement of care is required. Here we describe the design and the rational for the first cooperative prospective study in the Nort-West region of RF, RNWOHG-HD1. The key points of the protocol are d...
